Hou WH, et al. - In patients with type 2 diabetes, authors gauged the supposed link between dipeptidyl peptidase-4 inhibitor (DPP-4i) use and fracture risk. Study participants were patients with type 2 diabetes who were stable metformin users. The premise that DPP-4i usage is correlated with a reduced risk of all-cause fractures and upper extremity fractures in these patients was supported in the findings. Across sex and age stratifications, the aforementioned associations of DDP-4i use with fracture were sustained.